|
Post by bradleysbest on Jan 11, 2016 14:30:37 GMT -5
No they lost the right of first refusal.
|
|
|
Post by trondisc on Jan 11, 2016 14:31:41 GMT -5
I strongly believe BK is off the table. They have enough cash to shop assets and even entertain competitive bidding. TS is very valuable. Afrezza is likewise valuable if handled properly. Inventory and factory are also valuable. It does not need to be a fire sale. There's enough cash on hand to take their time and do it right. If you are in under $4.50 I think you're likely to come out of this at or close to whole. Well... that's my hope. Totally agree with this target. Selling all of MNKD IP (Afrezza, etc) + property will equate to only $5 PPS or $4.50. Anyone that thinks selling MNKD for over $5 PPS is out of their mind.
|
|
|
Post by kbrion77 on Jan 11, 2016 14:39:35 GMT -5
|
|
|
Post by 4allthemarbles on Jan 11, 2016 14:43:34 GMT -5
I strongly believe BK is off the table. They have enough cash to shop assets and even entertain competitive bidding. TS is very valuable. Afrezza is likewise valuable if handled properly. Inventory and factory are also valuable. It does not need to be a fire sale. There's enough cash on hand to take their time and do it right. If you are in under $4.50 I think you're likely to come out of this at or close to whole. Well... that's my hope. Totally agree with this target. Selling all of MNKD IP (Afrezza, etc) + property will equate to only $5 PPS or $4.50. Anyone that thinks selling MNKD for over $5 PPS is out of their mind. At this point $5 would be great. Even $4.50 is a great number, I just don't know how to get there. It's just what others are willing to pay with blood in the water. Generosity doesn't tend to coincide with the pharma industry.
|
|
|
Post by mnkdmorelong on Jan 11, 2016 14:49:39 GMT -5
Totally agree with this target. Selling all of MNKD IP (Afrezza, etc) + property will equate to only $5 PPS or $4.50. Anyone that thinks selling MNKD for over $5 PPS is out of their mind. At this point $5 would be great. Even $4.50 is a great number, I just don't know how to get there. It's just what others are willing to pay with blood in the water. Generosity doesn't tend to coincide with the pharma industry. Na na na! I see buyout creep here. Now you are up to $5.00 ps. As a reminder, Afrezza is a flop and TS has only one application and it is a flop. The earlier inhaled product (Exubera) was also a flop. It's one big flophouse. The ultimate BO price will be closer to a flophouse price rather than prime real estate.
|
|
|
Post by 4allthemarbles on Jan 11, 2016 14:53:31 GMT -5
Buyout creep?
|
|
|
Post by 4allthemarbles on Jan 11, 2016 14:57:39 GMT -5
At this point $5 would be great. Even $4.50 is a great number, I just don't know how to get there. It's just what others are willing to pay with blood in the water. Generosity doesn't tend to coincide with the pharma industry. Na na na! I see buyout creep here. Now you are up to $5.00 ps. As a reminder, Afrezza is a flop and TS has only one application and it is a flop. The earlier inhaled product (Exubera) was also a flop. It's one big flophouse. The ultimate BO price will be closer to a flophouse price rather than prime real estate. What do you mean- the board or are you referring to my post?
|
|
|
Post by kc on Jan 11, 2016 15:01:26 GMT -5
Go back to the WSJ announcement on 1/5/2016. They didn't report this with out some knowledge of the situation. I like Al Mann but we all know that the company needs a future and Afrezza needs a Pharma who can deliver to the market a blockbuster product. Al Mann and the Board know what they have to do to save the Company and product. They can't do it as an independent company. So Wall Street knows, The hedges know and investment bankers know. They company either has to be sold or a Bankruptcy is ahead. I don't believe that Al lets the ship sink like the titanic. But what do I know? I'm just a dumb investor. Mannkind, Sanofi End Diabetes Drug Deal DOW JONES & COMPANY, INC. 10:05 AM ET 1/5/2016
Symbol Last Price Change MNKD 1.05<image003.png> -0.4 (-27.59%) SNY 42.23<image003.png> +0.03 (+0.07%) QUOTES AS OF 11:05:27 AM ET 01/05/2016 MannKind Corp. (MNKD) on Tuesday announced the termination of its licensing pact with Sanofi-Aventis in the U.S. for the development and sale of its inhaled diabetes medicine Afrezza and signaled that it might look to sell the drug.
Shares of the company tumbled 28% in early trading. Over the past three months, shares have dropped 67%, including Tuesday's decline. MannKind (MNKD) said that it and Sanofi(SNY) would begin transition talks to return Afrezza to MannKind(MNKD) over the next three to six months, with the termination effective no later than July 4. As a result of squashed deal, MannKind(MNKD) said it is reviewing its strategic options for Afrezza. The evaluation of options typically include a full or partial sale.The company struck the marketing deal with French drug company Sanofi(SNY) in August 2014. In its most recent quarterly earnings call with analysts and investors, then-Chief Executive Hakan Edstrom said MannKind(MNKD) was "disappointed with the growth of Afrezza sales during the first nine months of the year," pointing to insurance reimbursement issues and slow uptake. Mr. Edstrom stepped down as CEO in November. Write to Lisa Beilfuss at lisa.beilfuss@wsj.com (END) Dow Jones Newswires
01-05-161105ET
Copyright (c) 2016 Dow Jones & Company, Inc. Read more: mnkd.proboards.com/user/284/recent#ixzz3wy2rxLna
|
|
|
Post by mnkdmorelong on Jan 11, 2016 15:03:49 GMT -5
Yes, the price now is $0.67 ps. If we get up to $5, a lot of longs are even. It's the creeping up of the price to a level that is better for longs based on nothing except hope. This will be a distressed merchandise sale. Nothing in MNKD is producing a profit. For profits to flow, the new owner must invest heavily. The backdrop shows two other companies (SNY and PFE) who poured 8 figures cash each and failed to profit from inhaled insulin.
|
|
|
Post by _neil on Jan 11, 2016 15:10:26 GMT -5
It's ludicrous to even think about putting the people running MNKD at Jobs's level. They don't have the imagination, conviction or fortitude (or even time in their life) to make their product a success let alone building the next apple. If MNKD gets close to 1B in valuation, I will eat(ingest) a dirty shoe and upload it to youtube.
|
|
|
Post by 4allthemarbles on Jan 11, 2016 15:10:28 GMT -5
I wasn't sure what you meant. Lots and lots so speculation. I think a BO is smarter the BK. I have also read anything from $2 to $5, which is probably high unless the sell TI as well.
There's a lot going on now- hard to see. We have cash for at least two quarters, but the road is not clear. I think everyone is wanting good news, it at least to get out of this not getting hurt so bad.
It's also ok to say we don't know what's going to happen.
|
|
|
Post by ricguy on Jan 11, 2016 15:15:35 GMT -5
I would be happy as a pig in sh*t if we got a buyout for $5. My how things have changed. I just don't see us getting $5, more like half if we are lucky but what do I know, I'm the dope that invested in this co with an avg pps of around $5. The impression I am getting now is no-one will want this. I hope I am wrong but we have seen 0 TS deals so there must be a reason why and Afrezza might have to many obstacles to take on for any co to deal with no matter how good it works. I do think it's either BO or BK. Such a shame, such a promising and great treatment about to go in the dumpster. Welcome to big pharma. And they say there is no cure for cancer. Yeah ok.
|
|
|
Post by kc on Jan 11, 2016 15:17:09 GMT -5
I wasn't sure what you meant. Lots and lots so speculation. I think a BO is smarter the BK. I have also read anything from $2 to $5, which is probably high unless the sell TI as well. There's a lot going on now- hard to see. We have cash for at least two quarters, but the road is not clear. I think everyone is wanting good news, it at least to get out of this not getting hurt so bad. It's also ok to say we don't know what's going to happen. If a BO occurs it will be for the entire company.
|
|
|
Post by greg on Jan 11, 2016 15:17:20 GMT -5
Yes, the price now is $0.67 ps. If we get up to $5, a lot of longs are even. It's the creeping up of the price to a level that is better for longs based on nothing except hope. This will be a distressed merchandise sale. Nothing in MNKD is producing a profit. For profits to flow, the new owner must invest heavily. The backdrop shows two other companies (SNY and PFE) who poured 8 figures each and failed to profit from inhaled insulin. Not that it really matters but PFE spent more than $3,000,000,000 and about a decade on its inhaled insulin, and that's $3 billion with a B. What has SNY put into its inhaled insulin? About 15 months and $400 million, that's it. Putting them into the same boat is rather silly. As to "distressed merchandise sale," things aren't that clean cut. MannKind may be strapped and not have many options. But this may not be all that relevant if several, or even just two, potential acquirers decide the company's various asset are attractive. You may have concluded that Afrezza is spoiled merchandise, many would disagree.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 11, 2016 15:32:08 GMT -5
I strongly believe BK is off the table. They have enough cash to shop assets and even entertain competitive bidding. TS is very valuable. Afrezza is likewise valuable if handled properly. Inventory and factory are also valuable. It does not need to be a fire sale. There's enough cash on hand to take their time and do it right. If you are in under $4.50 I think you're likely to come out of this at or close to whole. Well... that's my hope. Totally agree with this target. Selling all of MNKD IP (Afrezza, etc) + property will equate to only $5 PPS or $4.50. Anyone that thinks selling MNKD for over $5 PPS is out of their mind. Who in their right mind is going to pay $5 what is wrong with some of you lucky if we get $2
|
|